MeiraGTx agreed to buy back full rights to bota-vec, an eye gene therapy previously backed by Johnson & Johnson after a Phase 3 failure in X-linked retinitis pigmentosa. The deal brings the asset back to MeiraGTx for $25 million upfront, positioning it for future strategy changes despite last year’s setback. Meanwhile, Storm Therapeutics raised $56 million in a Pfizer-backed Series C and launched a Phase 2 trial in sarcoma patients. The combination of MeiraGTx’s rights reset and Storm’s new clinical start reflects two distinct funding-and-portfolio moves: reclaiming failed assets for rework versus pushing new candidates forward with fresh capital. Together, the moves show how investors and sponsors manage risk in gene therapy and oncology—either by renegotiating control after clinical failures or accelerating early development with targeted trial plans.